Captor Therapeutics
Business Services · Poland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Dunska 11, Wroclaw, Lower Silesian Voivo...Phone Number
+48 537869089Website
www.captortherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Captor Therapeutics
Captor Therapeutics is a biopharmaceutical company based in Basel, Switzerland, and Wroclaw, Poland, specializing in Targeted Protein Degradation (TPD) technology to develop innovative therapeutics for severe conditions such as cancer and autoimmune diseases. The company utilizes its Optigrade platform, which combines advanced protein engineering, structural biology, and molecular modeling, to expedite drug discovery and address high unmet medical needs. By focusing on undruggable molecular targets, Captor aims to provide new treatment options and improve patient outcomes. Their multidisciplinary expertise positions them as leaders in the field of early drug development.Explore more
Captor Therapeutics Org Chart
AS
Senior Research & Development Specialist
RP
Senior Scientist
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Captor Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Captor Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Captor Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Captor Therapeutics
Funding: Get notified immidiatlly once Captor Therapeutics has new funding data
Product Launch: Get notified when Captor Therapeutics launches new products
Check if Captor Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Captor Therapeutics had a recent Job posting/layoffs
Captor Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Captor Therapeutics
Find more new buyers
Company Profile Activity
Activity Insights
Captor Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Captor Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Captor Therapeutics.
Captor Therapeutics Tech Stack
A closer look at the technologies used by Captor Therapeutics
Captor Therapeutics News & Media
Captor Therapeutics Announces Three-Year Strategic Objectives
WROCŁAW, Poland, March 07, 2023 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (“Captor”) (WSE:CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today announced its strategic objectives for the period 2023 to 2025 aimed at building a clinical stage, major international player in the rapidly growing TPD space.Ono Pharmaceutical and Captor Therapeutics Announce Drug Discovery Collaboration to Develop Small Molecule Protein Degraders for the Treatment of Neurodegenerative Diseases
WROCŁAW, Poland, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE: CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today announces a worldwide drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (Ono), to develop novel small molecule degrader drugs against a currently undrugged target of interest in neurodegenerative diseases.Captor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate to Enter CTA/IND-Enabling Studies for the Treatment of Hepatocellular Carcinoma
WROCŁAW, Poland, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for the treatment of cancer and autoimmune diseases, today announces that it has selected CPT-6281 as drug candidate for the CT-01 project, which will initially focus on the clinical development of the asset as a TPD treatment against hepatocellular carcinoma (HCC). The announcement of the drug candidateCaptor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for hepatocellular carcinoma
WROCLAW, Poland, April 12, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer and autoimmune diseases, today announces the molecular targets of one of its core pipeline projects designated CT-01, which is focused on the development of TPD therapy for hepatocellular carcinoma (HCC).
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Captor Therapeutics
Sign Up For FreeTo access detailed company insights
Captor Therapeutics is a biopharmaceutical company based in Basel, Switzerland, and Wroclaw, Poland, specializing in Targeted Protein Degradation (TPD) technology to develop innovative therapeutics for severe conditions such as cancer and autoimmune diseases. The company utilizes its Optigrade platform, which combines advanced protein engineering,... Read More
